FDA approves Novoste's 60mm radiation source:
This article was originally published in Clinica
The US FDA has given Novoste the green light to market its Beta-Cath system with a longer 60mm radiation source, which is suitable for the treatment of long, diffuse in-stent restenosis. Patients with diffuse, in-stent restenosis typically have the worst clinical outcomes due to the complexity of their disease, says the Atlanta, Georgia firm. The Beta-Cath product line already includes 30-mm and 40mm radiation source lengths.
You may also be interested in...
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.